Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Greggors, my randomly assigned moniker of gf is different than gf’s assignment of gf. Unless, these are known unknowns..
BRIG IS a blockbuster! Check the sales!
Ariad had two drugs. one Ponatinib that was FDA approved before Takeda bought them out, and the drug for NSCLC Brignatinib that was in a ph3 trial and was approved shortly after Takeda bought the company. That second drug is what swayed Takeda. Unfortunately, Aurinia is just one trick pony. That reduces the desire for buyout. You only have one shot on goal.
We expect 2022 U.S. #LNG exports to increase 16% over 2021 levels, driven by strong global #naturalgas demand. #STEO go.usa.gov/xtdEY
We expect 2022 U.S. #LNG exports to increase 16% over 2021 levels, driven by strong global #naturalgas demand. #STEO https://t.co/GyecEjNVkj pic.twitter.com/ys8OO3xw2A
— EIA (@EIAgov) February 8, 2022
Ganz, that is the rub with Aurinia.. It’s a one trick pony. Zat knows that too..
Lilly looked and no dice..
I love gold now…
https://twitter.com/sp3cul8r/status/1490837533005324288?s=21
I would normally not want to own this, but now is the time..
Setting up nicely:
https://twitter.com/sp3cul8r/status/1490837533005324288?s=21
With the gargantuan deficit the US has, there’s only one directions can go.
AMRN- This might be worth consideration as an investment as Alex Denner is about to make his move..
Amarin has a big decision to make. How Sarissa Capital can help it move forward https://www.cnbc.com/2022/01/29/amarin-has-a-big-decision-to-make-how-sarissa-capital-can-help-it-move-forward.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
I just wish you could discover happiness in life. It I lived near you, I would gladly bring you to my church tomorrow. It would be a pathway to show you happiness that you would not forget. Spiritual.
“I would think that the Modus of his Operandi is variable, based on the specific company.
Variables such as the value of assets (Voclosporin), financial reserves, the state of the market in general, current MA activities, and no doubt there are others. “
Zat, Really?????
Answered……
Here is the MO of Peter Greene in selling previous companies:
$AUPH this tweet sums up PG’s signature move which is to file a $250 million dollar shelf, knock down the share price, award options and sell the company. They brought him in to do what he’s already done twice in his career which is facilitate BO https://t.co/hRQkWglyjQ
— 🧊Make Black Swans🧨 Great AGAIN 🐳 ❄️ (@RuniteDragon) January 29, 2022
Wow, zz is a super bull..
Obviously Jess. Just take them in order..
AUPH vs. KZR
How Silver and Gold started the year VS their current situation 🙃$SILVER $GOLD
— Sypie Silver (Sybren van der Hijden) (@SvdHijden) January 31, 2022
https://t.co/X0ZMpvYZgH
I expect they will add another two universities for more studies before any sales surface.
Here we go again. Make it work this time…
Aurinia Pharmaceuticals quick uptick on renewed takeover speculation on Biogen news https://seekingalpha.com/news/3793129-aurinia-pharmaceuticals-quick-uptick-on-renewed-takeover-speculation-on-biogen-news?source=copyToPasteboard
Finally, Jess and Ganz together.
Exactly..
IMPL- Impel Therapeutics monthly scrips since Q4 2021 launch:
$IMPL FACTS! pic.twitter.com/Qo1xeNv7vE
— burp🍺🍺🍺🍺🍺🍺🍺🍺 (@bUrRpPPP) January 21, 2022
I think you mean sales not income..
Tell you MIL, “she'll wake up one morning and it's all over.”
That is what should keep you up at night….
Never fall in love with your stock. After what happened with Ariad, I thought many here would not have repeated that. I guess I was wrong….
Between $10 and $2… 8^)
Jess, when do you think raise will happen? Asking for my mother-in-law..
HAL, (Trade) has reported earnings of 0.92 per share versus last year's earnings of 0.18 per share.
HAL, (Trade) has reported earnings of 0.92 per share versus last year's earnings of 0.18 per share.
May be a change..
AAII sentiment is the lowest in 10 years pic.twitter.com/4mFG6FXwyn
— zerohedge (@zerohedge) January 23, 2022
The Rising Influence of Declining Affluence:
STEM graduates (% all graduates). US: 18%, Iran 44%, India 33%, Russia 31%, Germany 37%. pic.twitter.com/DpokjNb5Et
— Policy Tensor (@policytensor) January 23, 2022
I didn’t do as good, but I dumped all mine in the $15’s. I came to the conclusion that modified fish oil is not an ironclad patentable compound.
$16.76 What on earth is this??
You all should have looked before you leaped…..imho..
Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights
Jan 18, 2022
PDF Version
Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range
Achieved Broad and Favorable Trudhesa™ Payer Coverage with Signed Agreements Covering 80% of U.S. Commercial Lives
Planned Initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in Q1 2022; Results anticipated Q4 2022
https://investors.impelnp.com/news-releases/news-release-details/impel-neuropharma-provides-updates-trudhesatm-launch-and-recent/
31 million migraine suffers in the US. Unique upper nasal delivery pod which targets blood vessel rich area. Achieves IV Efficacy for pain. Only 23 million shares in float. 80% owned by institutions.
Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights
Jan 18, 2022
PDF Version
Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range
Achieved Broad and Favorable Trudhesa™ Payer Coverage with Signed Agreements Covering 80% of U.S. Commercial Lives
Planned Initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in Q1 2022; Results anticipated Q4 2022
https://investors.impelnp.com/news-releases/news-release-details/impel-neuropharma-provides-updates-trudhesatm-launch-and-recent/
JPM is the largest health care conference in the world, and M&A activities are usually announced there. There were some.
23 million shares outstanding, 80% institutionally owned. FDA approved drug for migraines, with unique delivery mechanism for the nostrils. Only have 4 weeks of sales history in Q3 from approval, but it was robust. Q4 results we be pivotal event..
It will now be decided with Q4 sales results. Will Peter be a hero or zero in the eyes of the market? Won’t be long..